# Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

> **NCT04765449** · PHASE1 · COMPLETED · sponsor: **Thomas Jefferson University** · enrollment: 30 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Cytotoxic T Lymphocytes

## Key facts

- **NCT ID:** NCT04765449
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-15
- **Primary completion:** 2022-07-29
- **Final completion:** 2023-01-19
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04765449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04765449, "Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04765449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*